New Haven Connecticut Plans to File Vytorin Lawsuit

The city of New Haven, Connecticut, has indicated that they plan to file a Vytorin lawsuit against Merck and Schering-Plough to recover over $400,000 in prescription costs paid for employees who received the cholesterol drug that has been found to provide no medical benefit.

 
Vytorin is a combination drug that contains Zocor (simvastatin) and Zetia (ezetimibe). It was approved by the FDA in 2004 for treatment of cholesterol and it has grown into a blockbuster medication, with annual sales of $5 billion in 2007.

Earlier this year, a study found that Vytorin does not provide any benefit over the use of cheaper generic versions of Zocor.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The study, which followed 720 people with very high cholesterol levels, found that while Vytorin does lower cholesterol, there was no significant different between Vytorin users and users of Zocor alone in the reduction of plaque which can develop in the inner walls of the arteries. The build up of this plaque could potentially lead to an increased risk of a heart attack or stroke, which is the primary reason the cholesterol drugs are prescribed.

Generic versions of Zocor are available at a cost of only about $1 per pill, compared with nearly $3 per pill charged for Vytorin.

Vytorin class action lawsuits have been filed in several states on behalf of patients and medical insurers who paid for the drug. The cases seek reimbursement for the different between the cost of the prescription and what would have been paid for the generic drug, since Vytorin promised added benefits.

According to The New Haven Independent, New Haven’s top lawyer attempted to locate a class action lawsuit that the city could join, but did not find any. Therefore, the city put out a request for a proposal from outside product liability law firms who were interested in pursuing the city’s Vytorin lawsuit under a contingency fee agreement, where they would not be paid if they do not win.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns (Posted today)

The FDA has issued a safety communication warning that Zimmer Biomet CPT hip system femoral stems may increase the risk of femur fractures, calling for doctors to avoid its use when possible.

Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference
Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference (Posted yesterday)

The judge presiding over all Change Healthcare lawsuits filed in federal court is holding the first status conference of the litigation, which is expected to grow significantly as Change Healthcare data breach letters continue to be sent to impacted customers.

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted 2 days ago)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.